How has been the historical performance of Valiant Laborato?

Aug 08 2025 10:56 PM IST
share
Share Via
Valiant Laborato has experienced a significant decline in financial performance over the past three years, with net sales dropping from 333.91 Cr in March 2023 to 133.38 Cr in March 2025, resulting in increasing losses and negative profit figures. Despite reduced raw material costs, the company reported an operating profit of only 0.75 Cr in March 2025, down from 39.95 Cr in March 2023.
Answer:
The historical performance of Valiant Laborato shows a significant decline in net sales and profitability over the past three years. Breakdown: Valiant Laborato's net sales have decreased from 333.91 Cr in March 2023 to 182.06 Cr in March 2024, and further down to 133.38 Cr in March 2025. Total operating income followed the same trend, reflecting the drop in sales. The raw material costs also decreased significantly, from 277.28 Cr in March 2023 to 112.18 Cr in March 2025. Despite this reduction in costs, the company reported an operating profit (PBDIT) of only 0.75 Cr in March 2025, a stark contrast to the 39.95 Cr reported in March 2023. The profit before tax turned negative, showing -1.51 Cr in March 2025 compared to a profit of 38.14 Cr in March 2023. Consequently, the profit after tax also fell to -2.20 Cr in March 2025 from 29.00 Cr in March 2023. The earnings per share (EPS) reflected this downturn, dropping from 8.91 in March 2023 to -0.47 in March 2025. On the balance sheet, total liabilities increased from 212.97 Cr in March 2023 to 342.69 Cr in March 2024, while total assets also rose, indicating a growing financial burden. Cash flow from operating activities showed a decline, with a cash inflow of only 1.00 Cr in March 2024 compared to 56.00 Cr in March 2023, although financing activities provided a net cash inflow of 152.00 Cr in March 2024. Overall, Valiant Laborato's financial performance has deteriorated significantly over the past three years, marked by declining revenues and increasing losses.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Valiant Laboratories Ltd is Rated Strong Sell
Apr 02 2026 10:10 AM IST
share
Share Via
Valiant Laboratories Ltd is Rated Strong Sell
Mar 22 2026 10:10 AM IST
share
Share Via
Valiant Laboratories Ltd is Rated Strong Sell
Mar 11 2026 10:10 AM IST
share
Share Via